» Articles » PMID: 34045451

Human Stem Cells Harboring a Suicide Gene Improve The safety and Standardisation of Neural Transplants in Parkinsonian Rats

Overview
Journal Nat Commun
Specialty Biology
Date 2021 May 28
PMID 34045451
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Despite advancements in human pluripotent stem cells (hPSCs) differentiation protocols to generate appropriate neuronal progenitors suitable for transplantation in Parkinson's disease, resultant grafts contain low proportions of dopamine neurons. Added to this is the tumorigenic risk associated with the potential presence of incompletely patterned, proliferative cells within grafts. Here, we utilised a hPSC line carrying a FailSafe suicide gene (thymidine kinase linked to cyclinD1) to selectively ablate proliferative cells in order to improve safety and purity of neural transplantation in a Parkinsonian model. The engineered FailSafe hPSCs demonstrated robust ventral midbrain specification in vitro, capable of forming neural grafts upon transplantation. Activation of the suicide gene within weeks after transplantation, by ganciclovir administration, resulted in significantly smaller grafts without affecting the total yield of dopamine neurons, their capacity to innervate the host brain or reverse motor deficits at six months in a rat Parkinsonian model. Within ganciclovir-treated grafts, other neuronal, glial and non-neural populations (including proliferative cells), were significantly reduced-cell types that may pose adverse or unknown influences on graft and host function. These findings demonstrate the capacity of a suicide gene-based system to improve both the standardisation and safety of hPSC-derived grafts in a rat model of Parkinsonism.

Citing Articles

Advances in clinical translation of stem cell-based therapy in neurological diseases.

Wang Y, Cao Y, Xie W, Guo Y, Cai J, Huang T J Cereb Blood Flow Metab. 2025; :271678X251317374.

PMID: 39883811 PMC: 11783424. DOI: 10.1177/0271678X251317374.


Microfluidic chip systems for characterizing glucose-responsive insulin-secreting cells equipped with FailSafe kill-switch.

Izadifar M, Massumi M, Prentice K, Oussenko T, Li B, Elbaz J Stem Cell Res Ther. 2024; 15(1):486.

PMID: 39696686 PMC: 11656860. DOI: 10.1186/s13287-024-04059-7.


A systematic review of progenitor survival and maturation in Parkinsonian models.

Comini G, Dowd E Neural Regen Res. 2024; 20(11):3172-3178.

PMID: 39589166 PMC: 11881725. DOI: 10.4103/NRR.NRR-D-24-00894.


Integrating Mitochondrial Biology into Innovative Cell Therapies for Neurodegenerative Diseases.

Ore A, Angelastro J, Giulivi C Brain Sci. 2024; 14(9).

PMID: 39335395 PMC: 11429837. DOI: 10.3390/brainsci14090899.


Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes.

Eschenhagen T, Weinberger F Nat Cardiovasc Res. 2024; 3(5):515-524.

PMID: 39195938 DOI: 10.1038/s44161-024-00472-6.


References
1.
Barker R, Drouin-Ouellet J, Parmar M . Cell-based therapies for Parkinson disease—past insights and future potential. Nat Rev Neurol. 2015; 11(9):492-503. DOI: 10.1038/nrneurol.2015.123. View

2.
Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T . Neuron-like differentiation and selective ablation of undifferentiated embryonic stem cells containing suicide gene with Oct-4 promoter. Stem Cells Dev. 2008; 17(4):619-27. DOI: 10.1089/scd.2007.0235. View

3.
Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y . Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports. 2014; 2(3):337-50. PMC: 3964289. DOI: 10.1016/j.stemcr.2014.01.013. View

4.
Torres E, Monville C, Gates M, Bagga V, Dunnett S . Improved survival of young donor age dopamine grafts in a rat model of Parkinson's disease. Neuroscience. 2007; 146(4):1606-17. DOI: 10.1016/j.neuroscience.2007.03.037. View

5.
Kirkeby A, Nolbrant S, Tiklova K, Heuer A, Kee N, Cardoso T . Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease. Cell Stem Cell. 2017; 20(1):135-148. PMC: 5222722. DOI: 10.1016/j.stem.2016.09.004. View